[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":100},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100299898","neurocognition-in-patients-with-multiple-brain-metastases-treated-with-radiosurgery-100299898",false,"NCT03184038","Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery","Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery: A Phase II Study","Inclusion Criteria:\n\n* Pathologically proven solid tumor malignancy (except for small cell lung cancer \\[SCLC\\], germ cell tumor)\n* Karnofsky performance status \\>= 60\n* 1 to 10 brain metastases (mets) (no more than two lesions and\u002For cavities \\>= 3 cm in maximum diameter)\n* Maximum diameter of brain metastasis or resection cavity is 6 cm\n* Serum creatinine =\\\u003C 3 mg\u002FdL and creatinine clearance \\>= 30 ml\u002Fmin\n* Patients must have the psychological ability and general health that permits completion of the study requirements and required follow up; patients must be willing to complete neurocognitive assessments at pre-specified time points outlined in the protocol\n* Women of childbearing potential must have a negative beta-human chorionic gonadotropin (HCG) pregnancy test documented within 21 days prior to registration\n* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 4 months after last dose\n* Patient able to provide his\u002Fher own written informed consent and speak English\n\nExclusion Criteria:\n\n* Patient with diagnosis of glioma, or other World Health Organization (WHO) grade II - IV primary brain tumor\n* Prior brain surgery =\\\u003C 14 days prior to enrollment\n* Planned chemotherapy during radiosurgery\n* Leptomeningeal metastases\n* Intractable seizures while on adequate anticonvulsant therapy-more than 1 seizure per week for the past 2 months\n* Pregnant women","ALL","18 Years",{"count":19,"type":20},90,"ESTIMATED","INTERVENTIONAL",[23],"NA","This phase II trial studies the neurological function in patients with multiple brain metastases undergoing stereotactic radiosurgery (SRS) or stereotactic body radiation therapy (SBRT). Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Assessment of neurocognitive function may help show that SRS preserves neurological function in patients with multiple brain metastases better than SBRT.",[26,27],"Metastatic Malignant Neoplasm in the Brain","Metastatic Malignant Solid Neoplasm","RECRUITING","2026-05-20",{"date":31,"type":32},"2026-05-22","ACTUAL",{"date":34,"type":32},"2017-02-21",{"date":36,"type":20},"2026-09-30",{"name":38,"class":39},"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","OTHER",2,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},"100631513","optimizing-integrative-oncology-approaches-to-address-chemotherapy-induced-peripheral-neuropathy-in-gastrointestinal-gi-cancer-patients-a-smart-pilot-study-100631513","NCT07501663","Optimizing Integrative Oncology Approaches to Address Chemotherapy-induced Peripheral Neuropathy in Gastrointestinal (GI) Cancer Patients: A SMART Pilot Study","Inclusion Criteria:\n\n* Individuals must meet all the following inclusion criteria in order to be eligible to participate in the study:\n\n  * Age 18 years or older,\n  * Self-reported moderate (≥ 2\u002F4) numbness and tingling on the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Numbness and Tingling Severity Item in the previous week,\n  * At least three months since the last receipt of neurotoxic chemotherapy,\n  * Prior receipt of paclitaxel, docetaxel, cisplatin, oxaliplatin, nab-paclitaxel, or carboplatin for the treatment of stage I-III Gastrointestinal (GI) cancers,\n  * Speaking\u002Freading English.\n\nExclusion Criteria:\n\n* An individual who meets any of the following criteria will be excluded from participation in this study:\n\n  * Prognosis of ≤ 3 months,\n  * Documented neuropathy attributed to other causes (e.g., diabetic neuropathy),\n  * Intention to initiate a new prescription of duloxetine or other pain medications (i.e., first-line treatment for CIPN pain) during the study period; however, participants may continue on duloxetine or other pain medications if initiated at least 8 weeks before study enrollment, with no change in dose, and reporting unmanaged CIPN (i.e., ≥ 2\u002F4) PRO-CTCAE numbness\u002Ftingling severity in the last week,\n  * Currently using alcohol (ethyl), which means regular alcohol consumption (defined as ≥7 drinks\u002Fweek for women, ≥14 drinks\u002Fweek for men, or binge drinking \\>3 drinks per occasion at least weekly) within the past 3 months, or current alcohol use disorder or inability\u002Funwillingness to abstain from alcohol during the study intervention period,\n  * Currently using calcium salts, iron preparations or magnesium salts orally,\n  * With thyroid disorders, particularly those with hypo- or hyperthyroidism,\n  * With thiamine deficiency, as assessed and verified by the physician.",{"count":48,"type":20},60,[23],"The objective of the proposed pilot is to test the feasibility, acceptability, and preliminary efficacy of a 16-week sequential, multiple assessment randomized trial (SMART), which includes virtual Tai Chi\u002FQi Gong or α- Lipoic acid (ALA) supplements as an initial treatment, and acupuncture as the additional treatment, that examines a stepped-care intervention to address CIPN.",[52],"Peripheral Neuropathy",[54,55,56,57,58,59,60,61,62],"Gastrointestinal","Peripheral Neuropathy in Gastrointestinal","Chemotherapy-induced Peripheral Neuropathy","CIPN","Tai Chi","ALA","Qi Gong","Acupuncture","SMART","2026-04-09",{"date":65,"type":32},"2026-04-14",{"date":67,"type":32},"2026-01-20",{"date":69,"type":20},"2027-04",{"name":38,"class":39},1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":83,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":71},"100591019","leveraging-lung-cancer-screening-to-optimize-screening-outcomes-and-copd-management-copd-in-lcs-registry-100591019","NCT06974981","Leveraging Lung Cancer Screening to Optimize Screening Outcomes and COPD Management: COPD in LCS Registry","COPD in LCS","Inclusion Criteria:\n\n* • \\* Eligible for lung cancer screening by USPSTF 2021 criteria including age 50-80 years and currently or formerly smoking with at last 20 pack-years of smoking history at the time of consent\n\n  * Willingness to participate in an observational clinical trial and to be contacted about future ancillary studies that could include interventional clinical trials\n  * Ability to tolerate study procedures\n  * Ability to provide informed consent\n  * Clinical Lung Cancer Screening CT performed at the University of Michigan within the last year\n  * Meets one of the three following criteria: 1) Prior Diagnosis of COPD in the EMR 2) Prior pulmonary function meeting criteria for COPD (FEV1\u002FFVC ≤ 0.70) or 3) LAA\\>1% on lung cancer screening CT scan\n\nExclusion Criteria:\n\n* The presence of a respiratory condition other than COPD or asthma, or of a comorbid condition that in the judgment of the investigator may be the principal cause of respiratory symptoms (e.g. dyspnea or decreased exercise tolerance)Severe asthma, which is defined as any of the following:\n\n  * Current (i.e. at the time of the visit) GINA Step 4 or higher therapy (medium dose ICS\u002FLABA or high dose ICS or add-on LAMA; medium dose = \\>250 fluticasone propionate =100 fluticasone furoate, \\>200 beclomethasone, \\>400 budesonide, \\>220 mometasone). We will accept low-dose ICS\u002FLABA or medium dose ICS or\n  * 3 or more unscheduled healthcare visits (provider\u002Furgent care\u002FER) for asthma in the past 12 months or\n  * One asthma hospitalization in the past 12 months\n\n    * Concurrent participation in a therapeutic trial where treatment is blinded\n    * Active pregnancy. Documentation of birth control will be required for pre-menopausal women\n    * Cognitive dysfunction that prevents the participant from completing study procedures\n    * BMI \\> 35 kg\u002Fm2 at baseline, due to the effects of body weight on CT scan quality\n    * Current illicit substance abuse, including cannabis smoking\n    * Any illness expected to cause mortality in the next 3 years\n    * Any implanted metallic devices or prosthesis above the waist that could degrade thoracic CT scan quality\n    * History of thoracic radiation or thoracic surgery with resection of lung tissue\n    * Participants who present with an acute exacerbation of COPD, either solely participant-identified or that has been clinically treated, in the last 30 days can be rescreened for the study once the 30-day window from end of drug therapy has passed\n    * Participants who present with current use of acute antibiotics or steroids can be rescreened for the study \\>= 30 days after discontinuing acute antibiotics\u002Fsteroids. This restriction does not apply to participants who are on chronic prednisone therapy of \\\u003C10 mg per day or \\\u003C20 mg every other day or participants who are currently on chronic, prophylactic, or suppressive antibiotic therapy","50 Years","80 Years",{"count":82,"type":20},420,"12 Months","OBSERVATIONAL","The COPD in LCS Registry will identify and characterize individuals who have functional or radiographic evidence of COPD and are receiving lung cancer screening. Clinical information will be obtained from study participants including symptom burden, lung cancer risk, spirometry, imaging characteristics, and peripheral blood eosinophils.",[87,88],"COPD","Chronic Obstructive Pulmonary Disease",[87,90,91],"Lung Cancer Screening","pulmonary function","2026-02-27",{"date":94,"type":32},"2026-03-03",{"date":96,"type":32},"2025-01-02",{"date":98,"type":20},"2027-12-30",{"name":38,"class":39},""]